the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
March 18, 2023 – Valtrex (Valacyclovir) is an antiviral medication used to treat outbreaks of herpes simplex or herpes zoster (shingles). It is also used to prevent cytomegalovirus following a kidney transplant in high risk cases. It is a prodrug, …
Canada: DRESS Syndrome associated with Valtrex (Valacyclovir) Read more »
August 13, 2022 – Breast cancer: Is BIA-ALCL increasing in women in the US? Over the last couple of years, the recognition of an seemingly increased rate of incidence of Anaplastic Large-Cell Lymphoma (ALCL) in woman who received breast implants …
Breast cancer: Is BIA-ALCL increasing in women in the US? Read more »
May 08, 2022 – Umbralisib (Ukoniq) is a medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib (Ukoniq) inhibits multiple kinases. In biochemical and cell-based assays, Umbralisib inhibited PI3Kδ and casein kinase CK1ε. PI3Kδ is expressed in …
Umbralisib (Ukoniq): Drug recall because increased risk of patient death Read more »
December 13, 2010 – We learn today that the European Medicines Agency (EMEA) has been informed of Pfizer’s decision to voluntarily withdraw Sitaxentan [Thelin] from the market worldwide further to new information on two cases of fatal liver injury. Pfizer …
October 08, 2010 – Today, we learn that Abbott Laboratories and FDA notified healthcare professionals and patients about the voluntary market withdrawal of Sibutramine [Meridia], an obesity drug, from the U.S. market because of clinical trial data indicating an increased …
Sibutramine [Meridia]: Market Withdrawal Due to Risk of Serious Cardiovascular events Read more »
September 24, 2010 – Please find below a very significant announcement by the European Medicines Agency (EMEA) regarding the market suspensions of Avandia throughout the European Union. 09/23/2010 – The European Medicines Agency today recommended the suspension of the marketing …
September 20, 2010 – We learn today from a press release by the American Food and Drug Administration (FDA) the following (text adapted): Aromatase inhibitors in products marketed as dietary supplements are being recalled, including the products Arom-X, Arom-X UTT, …
Recall of Products Marketed as Dietary Supplements Containing Aromatase Inhibitors Read more »
June 21, 2010 – FDA notified healthcare professionals that results from a recent clinical trial raised new concerns about the product’s safety, and the drug failed to demonstrate clinical benefit to patients enrolled in trials. Background: Gemtuzumab Ozogamicin [Mylotarg], indicated …
Gemtuzumab Ozogamicin [Mylotarg]: Market Withdrawal Read more »